Oncotarget

Reviews:

Ubc13: the Lys63 ubiquitin chain building machine

Curtis D. Hodge, Leo Spyracopoulos and J. N. Mark Glove _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:64471-64504. https://doi.org/10.18632/oncotarget.10948

Metrics: PDF 4007 views  |   HTML 4398 views  |   ?  


Abstract

Curtis D. Hodge1, Leo Spyracopoulos1 and J. N. Mark Glover1

1 Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada

Correspondence to:

J. N. Mark Glover, email:

Keywords: Ubc13, ubiquitination, Mms2, Uev1A, RING E3 ligase

Received: June 01, 2016 Accepted: July 19, 2016 Published: July 29, 2016

Abstract

Ubc13 is an ubiquitin E2 conjugating enzyme that participates with many different E3 ligases to form lysine 63-linked (Lys63) ubiquitin chains that are critical to signaling in inflammatory and DNA damage response pathways. Recent studies have suggested Ubc13 as a potential therapeutic target for intervention in various human diseases including several different cancers, alleviation of anti-cancer drug resistance, chronic inflammation, and viral infections. Understanding a potential therapeutic target from different angles is important to assess its usefulness and potential pitfalls. Here we present a global review of Ubc13 from its structure, function, and cellular activities, to its natural and chemical inhibition. The aim of this article is to review the literature that directly implicates Ubc13 in a biological function, and to integrate structural and mechanistic insights into the larger role of this critical E2 enzyme. We discuss observations of multiple Ubc13 structures that suggest a novel mechanism for activation of Ubc13 that involves conformational change of the active site loop.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10948